DOCK4-AS1: A Potential Drug Target and Biomarker (G100506413)

Target Name: DOCK4-AS1

NCBI ID: G100506413

DOCK4-AS1

Other Name(s): DOCK4 antisense RNA 1

DOCK4-AS1: A Potential Drug Target and Biomarker

Dock4 is a gene that encodes a protein known as DOCK4, which plays a critical role in the regulation of cell adhesion. The loss of DOCK4 has been implicated in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. As a result, targeting DOCK4 has become an attractive research focus. One potential drug target and biomarker for DOCK4 is the DOCK4-AS1 gene.

The DOCK4-AS1 gene

The DOCK4 gene encodes a protein that is involved in the regulation of cell adhesion and in the development of various diseases. The protein is composed of 1,942 amino acids and has a molecular weight of 21.1 kDa. It is expressed in various tissues and cells, including brain, heart, and pancreas. The protein is involved in the regulation of cell adhesion by interacting with several cell surface molecules, including cadherins, E-cadherins, and N-cadherins.

DOCK4-AS1 is a splice variant gene that has been identified in various genomic studies. It is located on chromosome 16 and has a gene expression level of 0.48 in humans. The DOCK4-AS1 gene has four exons, which are located on the fourth chromosome. The first exon encodes the amino acid residues 1-284, while the second exon encodes the amino acid residues 285-948. The last two exons encode the amino acid residues 949-1,942.

The DOCK4-AS1 gene has been implicated in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. For example, studies have shown that the loss of DOCK4 is associated with the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Additionally, the DOCK4 gene has also been implicated in the development of various cancers, including breast, ovarian, and colorectal cancers.

DOCK4-AS1 as a drug target

DOCK4 is a protein that has been shown to play a critical role in the regulation of cell adhesion, and the DOCK4-AS1 gene has been implicated in the regulation of cell adhesion. As a result, targeting DOCK4-AS1 may be a promising approach for the development of new drugs for various diseases.

One potential mechanism by which DOCK4-AS1 could be targeted with drugs is by modulating its activity. For example, drugs that inhibit the activity of DOCK4-AS1 could potentially interfere with its regulation of cell adhesion. Such drugs could potentially be used to treat neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

Another potential mechanism by which DOCK4-AS1 could be targeted with drugs is by modulating its expression. For example, drugs that induce gene expression levels of DOCK4-AS1 could potentially be used to treat diseases where DOCK4-AS1 is expressed at higher levels than normal. Such drugs could potentially be used to treat cancer, where DOCK4-AS1 is often overexpressed.

DOCK4-AS1 as a biomarker

DOCK4-AS1 has also been shown to be involved in the regulation of cell adhesion, and its expression levels have been implicated in the development of various diseases. As a result, DOCK4-AS1 has potential as a biomarker for certain diseases.

For example, DOCK4-AS1 has been shown to be involved in the regulation of cell adhesion in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease

Protein Name: DOCK4 Antisense RNA 1

The "DOCK4-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DOCK4-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets